Monday, July 11, 2022
HomeInvestmentBioharvest Sciences Grants Choice to Purchase 30,000 Shares

Bioharvest Sciences Grants Choice to Purchase 30,000 Shares


BioHarvest Sciences (CSE:BHSC), a biotechnology innovator, is concentrating on the worldwide market demand for pure merchandise that present shoppers with useful well being and wellness. This contains shopper merchandise starting from meals enriched with lively substances like antioxidants to cleaner and extra constant hashish merchandise. BioHarvest Sciences has developed biofarming, a proprietary breakthrough patented know-how, able to naturally-producing the lively substances of a plant with out having to develop the plant itself. The corporate has already confirmed the know-how within the quickly rising nutraceuticals market specializing in dietary dietary supplements and the useful meals and beverage substances market. Merchandise reminiscent of BioHavest Sciences’ VINIA®, which is predicated on crimson grapes, has clinically- confirmed useful advantages, has already positively impacted the lives of 1000’s of Israelis and is accredited on the market within the US.

The worldwide hashish market is anticipated to achieve US$66.3 billion by the tip of 2025, in keeping with a report by Grand View Analysis. A big portion of the expansion has been pushed by the adoption of hashish within the pharmaceutical trade as new merchandise have been developed to deal with extreme medical situations reminiscent of most cancers, Parkinsons, Alzheimers and arthritis. Nonetheless, points with constant hashish provide can have an effect on the long-term progress of the trade as extra international locations provoke hashish packages and legislative reforms, posing potential difficulties for licensed producers to offer sufficient high-quality merchandise to satisfy the demand.

BioHarvest Sciences Inc. believes that its biofarming know-how is the answer to the hashish provide and consistency downside. The know-how isolates the lively ingredient cells from the hashish plant earlier than multiplying (rising) them within the biofarming course of. The know-how can do that with out utilizing any solvent extraction, genetic modification or artificial molecular processing strategies. To facilitate its biofarming operation, BioHarvest Sciences Inc. has constructed a manufacturing facility that may produce roughly one ton of lively hashish ingredient powder (equal to the hashish plant dried bud) per 12 months in a 100-square-meter house. The corporate intends to extend its manufacturing to 10 tons per 12 months by 2022.

As of September 2019, the corporate produced its first hashish cells in suspension with a cannabinoid profile that was equivalent to the unique hashish plant with out rising the plant. Following a B2B enterprise mannequin, BioHarvest Sciences Inc. intends to promote its lively substances as a powder for repackaging and formulation to its shoppers. As well as, the corporate could License the know-how in an effort to speed up the trade adoption curve.


In December 2021, the corporate launched the information that it has now grown a major quantity (10kg) of hashish biomass, all grown in proprietary bioreactors and with out rising the plant. Following a B2B enterprise mannequin, BioHarvest Sciences Inc. intends to promote its lively substances as a powder for repackaging and formulation to its shoppers. As well as, the corporate could License the know-how in an effort to speed up the trade adoption curve.

BioHarvest Sciences has already demonstrated the feasibility and viability of the biofarming know-how via its commercially out there product known as VINIA®. In 2021, BioHarvest recorded US$2.4 million value of gross sales orders for VINIA®, an almost sixfold improve over 2020. The expansion is pushed by a rising buyer base in Israel, and a profitable ecommerce launch of VINIA® within the USA. The projected income this 12 months is between US$5 million to US7 million, which represents a major progress of two.5X-3.5X over 2021.

VINIA® is predicated on many research which have demonstrated that reasonable consumption of crimson wine daily is ready to have a optimistic affect on one’s total coronary heart well being because of wine’s wealthy polyphenol content material, particularly resveratrol. One 400mg capsule of VINIA® incorporates the identical quantity of resveratrol contained in a single full bottle of Purple Wine with out the sugar, energy or alcohol present in crimson wine. Customers can at the moment buy the powder via the web site in a 400-milligram every day dose after BioHarvest made it potential to additionally make VINIA® out there on-line in the USA, the world’s largest marketplace for nutraceutical dietary supplements.

At current, BioHarvest is unstoppable in disrupting industries with distinctive merchandise and options. After VINIA®’s immense gross sales success, the corporate has trademarked its proprietary non-GMO biotech platform know-how known as “Bio-Plant CELLicitation™,” changing “BioFarming”.

In an interview, BioHarvest CEO Ilan Sobel talked about Bio-Plant CELLicitation™, a platform know-how rising plant cells in industrial-scale bioreactors and eliciting particular molecules to supply distinctive botanical compounds with excessive human utility worth. Accoridng to Sobel, the distinctive platform know-how permits them to develop full-spectrum, non-GMO hashish.

“”We will play in so many alternative areas, not simply nutraceuticals, not simply the cannabinoid house, however in lots of different areas the place we’re capable of convey the facility of the plant to the folks,” Sobel mentioned.

Firm Highlights

  • Over $30 million has been invested in creating BioHarvest Sciences’ biofarming know-how
  • BioHarvest’s bio-superfood product VINIA® is designed to assist coronary heart well being and enhance blood circulation by leveraging compounds generally present in crimson wine
  • Biofarming know-how has the potential to ease bottlenecks within the hashish trade
  • BioHarvest has already produced six distinctive cannabinoids in suspension: THC, CBD, THCA, CBDA, CBN and CNC
  • BioHarvest Sciences intends to make the most of a B2B enterprise mannequin, supplying its lively ingredient merchandise as a powder for repackaging by its shoppers.
  • The present manufacturing capability of the corporate’s facility is 2 tons per 12 months, which the corporate goals to extend to 10 tons per 12 months.
  • Has efficiently created hashish trichomes on the suspension part
  • BioHarvest Sciences’ seasoned administration crew has a observe document of success

Administration Crew

Zaki Rakib – President and Chairman of the Board

Dr. Rakib is a serial entrepreneur and seasoned govt. He brings in depth expertise in a number of industries. Previous to BioHarvest Sciences, Dr. Rakib co-founded Terayon Communication Methods, led the corporate from inception as its CEO, and managed its progress from $2M to $380M in income. Terayon reached a $7B market capitalization in 2000 and was in a while acquired by Motorola. Previous to that, Mr. Rakib was a director of engineering at Cadence design techniques which acquired Helios S/W the place he served as CTO. Dr. Rakib holds a Ph.D. in Mechanical Engineering and a Ph.D. in Utilized Arithmetic.

Ilan Sobel – CEO

Ilan, brings in depth expertise in Common Administration, Worldwide Gross sales & Advertising and marketing, Manufacturing & Operations and management experience in constructing large-scale companies and billion- greenback manufacturers. For the previous 6 years, Ilan served as COO and transitioned to Chief Industrial Officer of Weissbeerger the place he performed a serious management function in constructing a disruptive BIG Information, IOT & Software program Firm servicing main Beverage gamers which was lately bought by ABInBev. Beforehand, Ilan served an 18-year stint as an Worldwide Worker of The Coca-Cola Firm, the place he performed a pivotal function in key senior management positions producing important income and revenue progress and enhancing model well being developments throughout numerous international markets together with the USA, China, South East and West Asia and South Africa.

Dr. Yochi Hagay – Co-Founder & CTO

With a Ph.D in Biotechnology and 20+ years of related expertise, main substantial analysis and growth packages in each pharma and biotech, Dr. Hagay has lead the event and implementation of BioHarvest’s know-how platform since inception. She beforehand labored in numerous management positions at BTG company which was acquired by FERRING Prescription drugs. Dr. Hagay makes a speciality of genetic engineering, molecular biology, tissue tradition, monoclonal antibodies and scientific trials. She is the writer and co-author of a number of peer-reviewed – printed in scientific papers.

David Ryan – Vice President of Investor Relations

David Ryan has in depth expertise in funding and public markets. For the previous 20+ years, he has been a part of in bringing a number of preliminary public choices to market. He has helped elevate each fairness and debt financings for quite a few public corporations in each major and secondary financings in addition to served on the board of public corporations and in numerous roles.

Eitan Popper – Strategic Adviser

Mr. Popper was the co-founder and President of MedReleaf Corp., which was acquired in 2018 for $2.5 billion USD. Previous to its acquisition, MedReleaf was one of many largest and most respected vertically built-in medical Hashish producers on the planet. Mr. Popper brings over 15 years of worldwide partnerships, entrepreneurial ventures, disruptive trade, large-scale venture growth, engineering and funding expertise. He holds a B.Sc. in Civil Engineering, a M.Sc. in Environmental Fluid Mechanics from Stanford College, and an MBA from the Recanati College of Enterprise.

Malkit Azachi – VP of Analysis & Improvement

Dr. Azachi brings 20 years of expertise in biochemistry, genetic engineering, tissue tradition, molecular biology, and scientific & pre-clinical trials. Previous to BioHarvest, He served as know-how Director at HealOr Ltd, a Biopharmaceutical firm creating topical therapeutics. Prior, he led product growth on the analysis and growth division of Colbar LifeScience, a Johnson & Johnson Firm. Dr. Azachi holds a Ph.D in microbiology from the Hebrew College of Jerusalem and a Put up-Doc in Molecular Biology of the cell from Weizmann Institute of Science.

Michal Sapir – VP of Regulatory Affairs

Michal Sapir brings 30+ years of expertise within the medical machine, pharma and biotechnology industries. She has beforehand served as Senior Director of Mission Administration at ColBar LifeScience Ltd., a Johnson & Johnson Firm. She actively participated in FDA conferences in an effort to outline regulatory pathways, FDA inspections and ISO Audits. She has broad expertise in scientific and animal research; and had previously served as Affiliate High quality Coordinator & Senior Medical Analysis Administrator in Eli Lilly (1995-2000). Michal Holds a Grasp of Science in Biochemistry.

Dr. David Brad – Advisory Board

Brady brings to the advisory board 30 years of expertise as an integrative and dietary medication practitioner and over 25 years in well being sciences academia. He’s a licensed naturopathic medical doctor in Connecticut and Vermont, is board licensed in useful medication and scientific diet, and is a fellow of the American Faculty of Diet. Dr. Brady has been the Chief Medical Officer of Designs for Well being, Inc. and likewise at the moment serves because the Chief Medical Officer for Diagnostic Options Labs, LLC. He was the long-time Vice President for well being sciences and Director of the Human Diet Institute and continues to function an affiliate professor of scientific sciences, on the College of Bridgeport in Connecticut. He has printed a number of peer-reviewed scientific papers and textbooks associated to power ache, autoimmunity, and useful gastroenterology. Moreover. Dr. Brady appeared on the plenary talking panels of among the largest and most prestigious conferences within the discipline together with; IFM, ACAM, A4M, ACN, IHS, AANP, AIHM, and lots of extra.

David Tsur – Advisor

Mr. Tsur is the co-founder of Kamada Ltd, a public firm listed on each the NASDAQ and Tel-Aviv Inventory Alternate. He served as its Chief Government Officer and on its Board of administrators for the reason that Firm’s inception in 1990. He at the moment serves as Deputy Chairman of the Board.

He additionally serves because the Chairman of Kanabo Group Plc, an organization listed on the London Inventory Alternate, which focuses on distributing Hashish-derived merchandise for medical sufferers and non-THC merchandise for CBD shoppers.

Steven Lehrer – Advisor

Steven at the moment sits on the Board of Administrators of two life science corporations, one not for revenue, and is a member of the College of Maryland’s Bioengineering Division Advisory Board. He offers technique and implementation recommendation to a number of organizations on numerous subjects from industrial efforts via operations, enterprise growth, product growth, portfolio planning to the institution of worldwide operations. Beforehand Steve was Head of Biologicals at Cipla Ltd., CEO of Cipla BioTec, President of Glycominds Ltd, EVP of Adamas Prescription drugs Inc., CEO of GeneOs Ltd, CEO at DNA Sciences, and was a division President of Monsanto. Steven additionally labored with McKinsey & Co., and Proctor & Gamble Company.

Chris Hadfield – Advisor

Hadfield brings 40 years of scientific expertise to the Canadian-Israeli biotech agency, which has developed and patented a plant bio-cell know-how, known as BioFarming, able to rising the lively and helpful plant based mostly substances at industrial scale, with out the necessity to develop the plant itself.

INN doesn’t present funding recommendation and the data on this profile shouldn’t be thought of a advice to purchase or promote any safety. INN doesn’t endorse or advocate the enterprise, merchandise, companies or securities of any firm profiled.

The data contained right here is for data functions solely and isn’t to be construed as a proposal or solicitation for the sale or buy of securities. Readers ought to conduct their very own analysis for all data publicly out there in regards to the firm. Prior to creating any funding resolution, it is strongly recommended that readers seek the advice of instantly with BioHarvest Sciences Inc. and search recommendation from a certified funding advisor.

Supply hyperlink



Please enter your comment!
Please enter your name here

Most Popular

Recent Comments